Pipeline and Portfolio
I-Mab's pipeline is comprised of two biologics portfolios and has a total of 12 innnovative assets currently：
2017 key milestone of the pipeline is to reach 3 IND submissions (2 of which are multi-regional clinical trials) and 2 subsequent clinical start. In 2018, the key milestone is highlighted by 5-6 clinical assets in Ph 1 or Ph 2 development and 6 planned IND submissions of novel antibodies in China and/or the US.
An "Out-Licensing" and "In-Licensing" strategy helps to maintain our pipeline dynamic and competitive globally.